TGTX - ティ―ジ―・セラピュ―ティクス （TG Therapeutics Inc.）

TG Therapeutics, Inc. (NASDAQ:NASDAQ:TGTX) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ETCompany ParticipantsJenna Bosco – Investor RelationsMichael Weiss – Chairman and…

TG Therapeutics press release (TGTX): Q4 GAAP EPS of -$0.39 misses by $0.14.Revenue of $0.08M (-96.6% Y/Y) misses by $1.52M."We anticipate that our cash, cash equivalents and…

TG Therapeutics (TGTX) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open.The consensus EPS Estimate is -$0.26 (vs

TG Therapeutics Inc. (NASDAQ:TGTX) price on Friday, February 24, fall -4.56% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $15.70. A look at the stock’s price movement, the close in the last trading session was $16.45, moving within a range at $15.62 and $16.2324. The beta value … Analysts Provide Insight Into TG Therapeutics Inc.’s (TGTX) Potential. Read More »

TGTX has seen its SMA50 which is now 18.08%. In looking the SMA 200 we see that the stock has seen a 96.36%. OWLT has seen its SMA50 which is … The post Drawing stocks: TG Therapeutics, Inc. (NASDAQ:TGTX -4.56%), Owlet, Inc. (NYSE:OWLT 5.79%) appeared first on Stocks Equity .

TG Therapeutics <> is trading lower after the FDA announced an ongoing investigation over the increased risk of death related to the companys cancer medicine

TG Therapeutics Inc (TGTX) shares closed this week 40.9% lower than it did at the end of last week. The stock is currently down 56.5% year-to-date, down 82.2% over the past 12 months, and up 74.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.6%, and the S&P 500 fell 3.5%. Trading Activity Shares traded as high as $15.26 and as low as $8.04 this week.Trading volume this week was 321.4% higher than the 10-day average and 584.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 175.7% The company's stock price performance over the past 12 months lags the peer average by 192.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Check out these penny stocks insiders are buying Losers ION Geophysical Corporation (NYSE: IO ) shares fell 53.6% to settle at $0.51 on Thursday. Epizyme, Inc. (NASDAQ: EPZM ) shares dipped 44.2% to close at $1.06 on Thursday after the company priced an underwritten public offering of 56,666,667 shares at $1.50 per share, before underwriting discounts. TG Therapeutics, Inc. (NASDAQ: TGTX ) dropped 40.5% to settle at $8.27 on Thursday. TG Therapeutics said the FDA imposed partial clinical hold on select studies of U2 and its components for CLL and NHL. Cyngn Inc. (NASDAQ: CYN ) tumbled 35.7% to close at $1.62. PetVivo Holdings, Inc. (NASDAQ: PETV ) fell 35% to close at $1.30. PetVivo recently announced distribution of its veterinary medical device, SPRYNG, by Vetcove, Inc. Advanced Human Imaging Limited (NASDAQ: AHI ) fell 33.8% to settle at $1.82. Advanced Human Imaging recently signed partnership with Activate Health OÜ. Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) dropped 33.6% to close at $0.6280.

TG Therapeutics Inc''s (NASDAQ: TGTX ) CEO Michael Weiss said that the FDA has placed a partial clinical hold on some combination candidate studies for leukemia and lymphoma. Speaking at the B. Riley Securities'' 2022 Virtual Oncology Investor Conference, Weiss disclosed that FDA placed partial holds on studies of the U2 combination UKONIQ … Full story available on Benzinga.com

TG Therapeutics, Inc. (TGTX) with the stream of -2.92% also noticed, India Oragenics, Inc. (OGEN) encountered a rapid change of -1.76% in the last hour of Tuesdays trading session. TG The post Hot Stock to Observe: TG Therapeutics, Inc. (NASDAQ:TGTX), Oragenics, Inc. (AMEX:OGEN) appeared first on Stocks Equity .

Dave & Busters Entertainment, Inc. (NASDAQ:PLAY) with the stream of -2.21% also noticed, India TG Therapeutics, Inc. (NASDAQ:TGTX) encountered a rapid change of -1.12% in the last hour of MONDAYs The post Stock on the Move: Dave & Busters Entertainment, Inc. (NASDAQ:PLAY), TG Therapeutics, Inc. (NASDAQ:TGTX) appeared first on Stocks Equity .

TG Therapeutics, Inc. (TGTX) with the stream of 2.78% also noticed, India AgEagle Aerial Systems, Inc. (UAVS) encountered a rapid change of 0.19% in the last hour of trading session. The post Up to Date Stock in Review: TG Therapeutics, Inc. (NASDAQ:TGTX), AgEagle Aerial Systems, Inc. (AMEX:UAVS) appeared first on Stocks Equity .

TG Therapeutics, Inc. (TGTX) with the stream of 0.59% also noticed, India Senseonics Holdings, Inc. (SENS) encountered a rapid change of 1.58% in the last hour of Wednesdays trading session. The post Stock Views And Recommendations: TG Therapeutics, Inc. (NASDAQ:TGTX), Senseonics Holdings, Inc. (AMEX:SENS) appeared first on Stocks Equity .

During Q1, TG Therapeutics ''s (NASDAQ: TGTX ) reported sales totaled $793.00 thousand. Despite a 2.07% in earnings, the company posted a loss of $88.73 million. In Q4, TG Therapeutics brought in $38.00 thousand in sales but lost $86.93 million in earnings. What Is ROCE? Changes in earnings and sales indicate shifts in TG Therapeutics''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and Full story available on Benzinga.com